Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Objectives. There is an urgent need for new agents with activity in platinum-and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. Patients and methods. Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B). Results. There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Ann A required red cell transfusions while on treatment. Conclusions. Exatecan is well tolerated in this poor prognosis g-roup of patients but only has modest single agent activity when administered in a daily regimen. (C) 2004 Elsevier Inc. All rights reserved.
Author(s): Clamp, A., Adams, M., Atkinson, R., Boven, E., Calvert, A. H., Cervantes, A., Ganesan, T., Lotz, J., Vasey, P., Cheverton, P., Jayson, G. C.
Publication type: Article
Publication status: Published
Journal: Gynecologic Oncology
Year: 2004
Volume: 95
Issue: 1
Pages: 114-119
ISSN (print): 0090-8258
ISSN (electronic): 1095-6859
URL: http://dx.doi.org/10.1016/j.ygyno.2004.06.047
DOI: 10.1016/j.ygyno.2004.06.047
Altmetrics provided by Altmetric
